Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient Repository (RADAR)

Note that you will be prompted to log in or register an account

Accession Number
HLB01900909a

Study Type
Epidemiology Study

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
2000-2003

NHLBI Division
DBDR

Clinical Trial URLs
https://clinicaltrials.gov/ct2/show/NCT00005278

Primary Publication URLs
https://www.ncbi.nlm.nih.gov/pubmed/15987350

Consent

Commercial Use Specimen Restrictions No

Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes

Genetic Use Of Specimens Allowed? Yes

Genetic Use Area Of Research Restrictions Yes

Specific Consent Restrictions
Some biospecimens are restricted to research related to transfusion safety and some biospecimens are not restricted.

Objectives

Determine if newly identified or emerging pathogens can be transmitted by transfusion.

Background

Earlier repositories such as the NHLBI-sponsored Transfusion-Transmitted Virus Study (TTVS) and the National Institutes of Health Clinical Center repository were vital to the investigation of viral hepatitis transmission following blood transfusion. Based on the success of these collections it was determined that a more contemporary donor-recipient repository was needed. The Retrovirus Epidemiology Donor Study (REDS) has been conducted since 1989. In the late 1990's it was commissioned to establish a new linked donor-recipient repository.

Participants

A total of 127,864 donation specimens were collected from 101,197 different donors. The majority are not linked to any recipient specimens in the repository. The repository contains 13,201 donation specimens from 12,408 donors that were transfused into 3,575 recipients who completed the follow-up visit. Specimens consist of plasma (in most cases) or serum and frozen whole blood samples.

Design

The REDS Allogeneic Donor and Recipient (RADAR) repository was established between 2000 and 2003 by 5 REDS blood centers, 2 CDC-supported blood centers and eight collaborating hospitals with a wide US geographical distribution. Specimens from consented donors were collected, components from their donations were routed to participating hospitals, and recipients of these units consented to provide enrollment and follow-up specimens for long-term storage.

Conclusions

At the time of its completion, RADAR was the largest linked donor-recipient repository in the US. It was designed to be of sufficient size to study the transfusion transmissibility of emerging infectious agents.

Additional Details

Available Biospecimens

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

Visits (Vials):

21Jul2023

	Serum	Plasma	Whole Blood	Total
Pre-Transfusion	1,093	13,071	3,441	17,605
Post-Transfusion	0	6,680	1,547	8,227
6 Month Post Transfusion Follow-Up	0	18,551	3,538	22,089
Donor	0	263,996	117,299	381,295

Visits (Subjects):

21Jul2023

	Serum
	Total number of subjects	Average volume (ml) per subject
Pre-Transfusion	595	2.42

	Plasma
	Total number of subjects	Average volume (ml) per subject
Donor	92,870	4.06
Pre-Transfusion	3,660	2.98
Post-Transfusion	1,556	3.35
6 Month Post Transfusion Follow-Up	3,554	3.16

	Whole Blood
	Total number of subjects	Average volume (ml) per subject
Donor	92,010	1.85
Pre-Transfusion	3,441	1.52
Post-Transfusion	1,547	1.49
6 Month Post Transfusion Follow-Up	3,537	1.49

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Specimens Only

Study Catalog

Study Publications (18)

Materials Available

Plasma
Serum
Whole Blood
More Details

Study Documents

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.